Locations:
SearchDr. Steven Nissen shares his take
Now that publication of the FOURIER trial of evolocumab has yielded the first large-scale clinical outcomes data for a PCSK9 inhibitor, the question naturally arises: “Who should be treated?”
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In this two-minute video, Cleveland Clinic Cardiovascular Medicine Chairman Steven Nissen, MD, shares his thoughts on that question and also sums up current understanding of the safety of intensive LDL cholesterol lowering with PCSK9 inhibitor therapy.
For a related video recap of all major PCSK9 inhibitor study presentations at the American College of Cardiology meeting (ACC.17), click here.
Advertisement
Advertisement
How our first century has impacted cardiovascular practice
Review offers comprehensive assessment of the landscape for wearables and more
Preserving trust in research requires vigilance and consensus around statistical nuances
Cardiac surgeon Patrick Vargo, MD, reflects on his first year as Cleveland Clinic staff
Improved risk prediction for patients is at the heart of Dr. Aaron Weiss’ research interests
Centralization would likely bring better outcomes, experts say, but may not be feasible
Dr. Daniel Burns on mentorship, robotic valve surgery, statistics and more
JACC review makes the case and outlines how to ensure oversight